NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Novavax, Inc. (NVAX) Stock Analysis

Novavax, Inc. (NVAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NVAX

$11.01

−$0.42 (−3.67%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NVAX with… →

NVAX Key Statistics

As of Oct 21, 2026
Trading
Open
$11.35
Previous Close
$11.43
Day's Range
10.99–11.46
52-Week Range
6.20–13.39
Volume
5.43M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.44
Valuation
Market Cap
$1.82B
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.32
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.39
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.58
Financials (FY)
Revenue (FY)
$1.12B+64.69%
Net Income (FY)
$440.30M
Profit marginThe share of revenue left as profit after all costs and taxes.
−59.87%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
164.95M
1-Year Return
+28.17%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
5.98M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NVAX closed at $11.01, +28.17% over 1 year.

Novavax, Inc. (NVAX) has a market capitalization of $1.82B.

In fiscal 2025, NVAX reported revenue of $1.12B.

NVAX Stock Return by Calendar Year

Novavax, Inc. (NVAX) 10-year return: what $10,000 became

1 year
$10,000 $12,817
+28.17%
5 years
$10,000 $793
−92.07%
10 years
$10,000 $3,622
−63.78%

If you had invested $10,000 in Novavax, Inc. (NVAX) 10 years ago, at the close on October 21, 2016, it would have been worth $3,622 at the close on October 21, 2026: −63.78% in total, −9.66% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+63.84%
2025−16.42%
2024+67.50%
2023−53.31%
2022−92.81%
2021+28.30%
2020+2,701.76%
2019−89.18%
2018+48.39%
2017−1.59%
2016 (partial year)−83.24%

As of October 21, 2026.

NVAX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.12B$440.30M39.2%
2024$682.16M−$187.50M−27.5%
2023$556.38M−$545.06M−98.0%
2022$1.60B−$657.94M−41.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.12B$1.05B$550.64M$440.30M39.2%
2024$682.16M$479.42M−$248.93M−$187.50M−27.5%
2023$556.38M$212.61M−$566.51M−$545.06M−98.0%
2022$1.60B$696.31M−$644.74M−$657.94M−41.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NVAX Valuation vs Biotechnology Median

Median of 608 stocks
MetricNVAXBiotechnology medianvs median
P/S ratio4.3913.300.3x the median
Profit margin−59.87%−38.31%21.6 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Novavax, Inc. (NVAX) is capitalised at $1.82B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 749.

The 52-week range on file runs from $6.20 to $13.39. NVAX last closed at $11.01 on October 21, 2026. That is −$0.42 (−3.67%) against the previous close. The latest close sits 77.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.12B. Against the prior fiscal year total of $682.16M, that is a change of +64.69%. The same year closed with net income of $440.30M. The reported profit margin is −59.87%. That is 21.6 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −1.58.

Across the 4 fiscal years on file, revenue moves from $1.60B in 2022 to $1.12B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.32. Measured against sales, the shares trade at 4.39 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +28.17%. Across 10 years the annualized return works out at −9.66%. Beta against the wider market is reported at 2.44. Daily returns over the trailing 10 years annualize to a volatility of 112.06%.

Growth & Income

No dividend is on file for NVAX.

2026 is still running; the total return is +63.84% year to date. The strongest complete calendar year on file is 2020 at +2,701.76%; the weakest is 2022 at −92.81%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Novavax, Inc. (NVAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Novavax, Inc. NVAX $1.82B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Novavax, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Novavax, Inc.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Visit website →